Roquefort Therapeutics making headway with siRNA | News Direct

Roquefort Therapeutics making headway with siRNA

Roquefort Therapeutics PLC
News release by Roquefort Therapeutics PLC

facebook icon linkedin icon twitter icon pinterest icon email icon London, UK | August 09, 2023 07:48 AM Eastern Daylight Time

 

Roquefort Therapeutics PLC (LSE:ROQ, OTCQB:ROQAF) chief executive Ajan Reginald speaks to Thomas Warner from Proactive after announcing the successful development of new small interfering RNA (siRNA) sequences.

 

Reginald says that siRNA holds immense potential as a cancer treatment, explaining that SiRNA binds to and blocks specific RNA, stopping the production of cancer-fueling substances and ultimately killing cancer cells. He suggests that the technology has been gaining traction since it received the Nobel Prize in 2006, and that Big Pharma is now actively seeking partnerships in the siRNA field.

 

Reginald goes on to say that for Roquefort Therapeutics, the significance of their recent developments lies in their early innovation and focus on STAT6, a key target in their research. The company acquired R&D company Oncogeni last year before STAT6 gained widespread recognition, giving them what he considers a competitive edge in intellectual property and development.

 

He goes on to give a brief overview of the projects Roquefort is currently focused on, concluding by saying that "we're always trying to find new targets... if we can be first to find a new target, that's when shareholders will see very large deals."

 

Contact Details

 

Proactive UK Ltd

 

+44 20 7989 0813

 

uk@proactiveinvestors.com

project media

Tags

HealthBiotechPharmaOncologyCancersiRNARNA